120 related articles for article (PubMed ID: 25730797)
1. Review: approaches to develop PLGA based in situ gelling system with low initial burst.
Ahmed T
Pak J Pharm Sci; 2015 Mar; 28(2):657-65. PubMed ID: 25730797
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
[TBL] [Abstract][Full Text] [Related]
3. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
Dong WY; Körber M; López Esguerra V; Bodmeier R
J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
[TBL] [Abstract][Full Text] [Related]
4. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
5. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
6. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.
Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A
J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947
[TBL] [Abstract][Full Text] [Related]
7. Reduction in burst release after coating poly(D,L-lactide-co-glycolide) (PLGA) microparticles with a drug-free PLGA layer.
Ahmed AR; Elkharraz K; Irfan M; Bodmeier R
Pharm Dev Technol; 2012; 17(1):66-72. PubMed ID: 20854130
[TBL] [Abstract][Full Text] [Related]
8. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer.
Brodbeck KJ; DesNoyer JR; McHugh AJ
J Control Release; 1999 Dec; 62(3):333-44. PubMed ID: 10528071
[TBL] [Abstract][Full Text] [Related]
9. In situ forming implants for the delivery of metronidazole to periodontal pockets: formulation and drug release studies.
Kilicarslan M; Koerber M; Bodmeier R
Drug Dev Ind Pharm; 2014 May; 40(5):619-24. PubMed ID: 24369747
[TBL] [Abstract][Full Text] [Related]
10. Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation.
Körber M; Bodmeier R
Eur J Pharm Sci; 2008 Nov; 35(4):283-92. PubMed ID: 18721875
[TBL] [Abstract][Full Text] [Related]
11. In-situ forming PLGA implants: Towards less toxic solvents.
Ramos F; Willart JF; Neut C; Agossa K; Siepmann J; Siepmann F
Int J Pharm; 2024 May; 657():124121. PubMed ID: 38621617
[TBL] [Abstract][Full Text] [Related]
12. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
13. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Colloids Surf B Biointerfaces; 2009 Nov; 74(1):340-9. PubMed ID: 19717287
[TBL] [Abstract][Full Text] [Related]
14. Drug release from injectable depots: two different in vitro mechanisms.
Wang L; Venkatraman S; Kleiner L
J Control Release; 2004 Sep; 99(2):207-16. PubMed ID: 15380631
[TBL] [Abstract][Full Text] [Related]
15. Co-Delivery of Atorvastatin Nanocrystals in PLGA based in situ Gel for Anti-Hyperlipidemic Efficacy.
Kurakula M; Ahmed TA
Curr Drug Deliv; 2016; 13(2):211-20. PubMed ID: 26549039
[TBL] [Abstract][Full Text] [Related]
16. A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery.
Yehia SA; Elshafeey AH; Elsayed I
J Liposome Res; 2012 Jun; 22(2):128-38. PubMed ID: 22091557
[TBL] [Abstract][Full Text] [Related]
17. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability.
Schoenhammer K; Petersen H; Guethlein F; Goepferich A
Int J Pharm; 2009 Apr; 371(1-2):33-9. PubMed ID: 19135512
[TBL] [Abstract][Full Text] [Related]
18. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
19. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism.
Wang L; Wang A; Zhao X; Liu X; Wang D; Sun F; Li Y
Int J Pharm; 2012 May; 427(2):284-92. PubMed ID: 22387369
[TBL] [Abstract][Full Text] [Related]
20. Analysis of initial burst in PLGA microparticles.
Allison SD
Expert Opin Drug Deliv; 2008 Jun; 5(6):615-28. PubMed ID: 18532918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
